[go: up one dir, main page]

AR053711A1 - Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion - Google Patents

Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion

Info

Publication number
AR053711A1
AR053711A1 ARP060101493A ARP060101493A AR053711A1 AR 053711 A1 AR053711 A1 AR 053711A1 AR P060101493 A ARP060101493 A AR P060101493A AR P060101493 A ARP060101493 A AR P060101493A AR 053711 A1 AR053711 A1 AR 053711A1
Authority
AR
Argentina
Prior art keywords
helicobacter
vaccines
antigen
porcine
circovirus
Prior art date
Application number
ARP060101493A
Other languages
English (en)
Inventor
John Ellis
Catherine Charreyre
Oliver Michel Martinon
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of AR053711A1 publication Critical patent/AR053711A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se basa en especies del gen de Helicobacter que están asociadas con la ulceracion gastroesofágica en cerdos. En particular, se ha utilizado una especie, H. cerdo, como fuente de material antigénico para el desarrollo de vacunas para el tratamiento de trastornos gastroesofágicos. Más ventajosamente, el Helicobacter y circovirus porcino asociados con el PMWS (síndrome de demedro multisistémico post destete) en cerdos son utiles para brindar vacunas de combinacion, a través de las cuales los inmunogenos derivados de ambos tipos de patogenos pueden cosuministrarse al animal meta par estimular la generacion de anticuerpos protectores e inmunidad. Por lo tanto, brinda vacunas que son utiles para el tratamiento de la ulceracion gastroesofágica y PMWS en porcinos. Por consiguiente, la presente incluye composiciones inmunogénicas y vacunas multivalentes, kits multivalentes, y métodos de inmunizacion o vacunacion combinados que hacen posible utilizar dichos programas de inmunizacion o vacunacion combinados. Reivindicacion 1: Una composicion inmunogénica para provocar una respuesta inmunologica contra una especie Helicobacter y circovirus porcino que comprende al menos un antígeno de Helicobacter y al menos un antígeno de circovirus porcino y un vehículo o excipiente veterinariamente aceptable. Reivindicacion 17: Un método para inducir una respuesta inmunologica contra una cepa de Helicobacter y un circovirus porcino, que consiste en administrar a un porcino una composicion inmunogénica de acuerdo con cualquiera de las reivindicaciones 1 a 16. Reivindicacion 18: Un kit para preparar una composicion inmunogénica de acuerdo con la reivindicacion 1 que comprende (i) al menos un antígeno de Helicobacter y (ii) al menos un antígeno de circovirus porcino, donde (i) y ii) se envasan por separado.
ARP060101493A 2005-04-15 2006-04-17 Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion AR053711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/107,219 US20060029617A1 (en) 1997-10-03 2005-04-15 Porcine circovirus and Helicobacter combination vaccines and methods of use

Publications (1)

Publication Number Publication Date
AR053711A1 true AR053711A1 (es) 2007-05-16

Family

ID=37027631

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101493A AR053711A1 (es) 2005-04-15 2006-04-17 Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion

Country Status (9)

Country Link
US (1) US20060029617A1 (es)
EP (1) EP1871884A2 (es)
CN (1) CN101198699A (es)
AR (1) AR053711A1 (es)
BR (1) BRPI0607551A2 (es)
CA (1) CA2604705A1 (es)
CL (1) CL2006000880A1 (es)
TW (1) TW200719912A (es)
WO (1) WO2006113372A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100879650B1 (ko) * 1997-12-11 2009-01-20 유니버시티 오브 사스카췌완 돼지로부터의 이유후 다기관계작용성 소모 증후군 바이러스
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
CN101048181A (zh) * 2004-08-13 2007-10-03 巴里·J·马沙尔 细菌递送系统
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
PT3127551T (pt) * 2005-12-29 2020-10-09 Boehringer Ingelheim Animal Health Usa Inc Composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
CN101558169B (zh) * 2006-12-15 2017-08-04 贝林格尔.英格海姆维特梅迪卡有限公司 以pcv2抗原治疗猪
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
JP2011508595A (ja) * 2007-12-31 2011-03-17 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子
EP2242511A4 (en) * 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CN102973932A (zh) * 2011-09-07 2013-03-20 普莱柯生物工程股份有限公司 猪繁殖与呼吸综合征、猪圆环病毒病与猪伪狂犬病三联灭活疫苗以及其制备方法
CN102406936A (zh) * 2011-11-22 2012-04-11 青岛易邦生物工程有限公司 一种鸡传染性鼻炎灭活疫苗佐剂
CN103893749A (zh) * 2012-12-29 2014-07-02 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN103920146A (zh) * 2013-01-14 2014-07-16 普莱柯生物工程股份有限公司 猪圆环病毒ⅱ型与猪伪狂犬病二联疫苗及其制备方法和应用
KR102409183B1 (ko) 2013-10-02 2022-06-15 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Ｐｃｖ2 ｏｒｆ2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
RO132299A3 (ro) 2017-06-06 2018-12-28 Fântână Raul Sorin Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active ()

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
DK1599164T3 (en) * 2003-02-03 2015-04-27 Cerebus Biolog Inc METHODS OF TREATMENT, PREVENTION AND DETECTION OF HELICOBACTER INFECTION

Also Published As

Publication number Publication date
US20060029617A1 (en) 2006-02-09
CN101198699A (zh) 2008-06-11
WO2006113372A2 (en) 2006-10-26
CA2604705A1 (en) 2006-10-26
EP1871884A2 (en) 2008-01-02
TW200719912A (en) 2007-06-01
BRPI0607551A2 (pt) 2009-09-15
CL2006000880A1 (es) 2009-08-07
WO2006113372A3 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
EE200100203A (et) Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
MX2018007860A (es) Vacunas recombinantes contra el zika.
PE20100366A1 (es) Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20030285A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
NO20015073D0 (no) Vaksiner
PE20080748A1 (es) Vacuna a base de los de cepas de neisseria
AR061152A1 (es) Vacuna recombinante contra virus de la lengua azul
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
BRPI0520330B8 (pt) adjuvante a base de ácido polinosínico-policitidílico
AR092896A1 (es) Composiciones inmunogenicas
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
MX2019003116A (es) Nueva vacuna contra la gripe porcina.
AR102548A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
AR126891A2 (es) Vacunas de subunidades de rotavirus, métodos de preparación y uso de las mismas
BR112023019301A2 (pt) Formulações de vacina de coronavírus
MX2007015933A (es) Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
CY1112149T1 (el) Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο

Legal Events

Date Code Title Description
FB Suspension of granting procedure